OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Publication Speed (median values for papers published in 2023): Submission to First Decision: 5.1 weeks; Submission to Acceptance: 17.0 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021 2020 2019 2018 2017

Special Issue

Genetics and Genomics of Acute Promyelocytic Leukemia

Submission Deadline: June 15, 2020 (Open) Submit Now

Guest Editor

RACHA EL-HAJJ GHAOUI, Ph.D

Senior Scientist, Department of Cytogenetics, Sydney Genome Diagnostics, Sydney, Australia

Website | E-Mail

Research Interests: Fluorescence In Situ Hybridisation; human cytogenetics; oncology and blood cytogenetics

About This Topic

Acute promyelocytic leukaemia (APL) is an aggressive and rare sub-type of acute myeloid leukaemia (AML) and accounts for only 10% of all AML diagnoses. PML-RARA gene fusion most often arises via the classic t(15;17)(q24.1;q21.2) translocation. This special issue will cover the unique cases of paediatric and adult APL and highlights the unusual findings in this type of leukaemia and its variants including therapy related APL..

In this issue, you are invited to present all the clinical aspects of APL from diagnosis to treatment. Also, discuss the genetics and genomics (genome sequencing) background of this leukaemia subtype, including gene mutation (i.e. FLT3) status which can predict an early death in APL. It would also be important highlighting the Cytogenetics [karyotype and fluorescence in situ hybridisation] and molecular testing [RT-PCR] for a rapid diagnosis of APL which is important due to the high risk of disseminated intravascular coagulation leading to internal bleeding and death. Immediate treatment with both all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has improved the prognosis for APL patients, especially if consolidated with anthracycline, leading to a disease-free survival..

All new studies and technologies which have been applied to improve disease classification, clinical care, and novel therapeutic approaches in AML/APL would make a significant contribution to this special issue.

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (genetics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!

Newsletter

TOP